Guided Therapeutics Inc. Completes Enrollment for US FDA Clinical Trial of LuViva Cervical Scan Device, Begins Data Analysis
Reuters
Aug 13
Guided <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Completes Enrollment for US FDA Clinical Trial of LuViva Cervical Scan Device, Begins Data Analysis
Guided Therapeutics Inc. has announced the completion of patient enrollment for its clinical trial involving the LuViva Advanced Cervical Scan, a device designed for the rapid and painless detection of cervical cancer using patented biophotonic technology. The study, which was conducted across four clinical sites, enrolled approximately 430 patients, meeting the company's primary objective for 2025. The data analysis phase is now underway and includes an external review of biopsy samples, data entry from study case report forms, and statistical analysis as per the study protocol. The company anticipates filing the clinical report with the FDA later this year. The trial reported no adverse events linked to the use of LuViva, supporting its designation as a non-significant risk device by the FDA. Results from the statistical analyses are expected to be presented in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813058714) on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.